Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1995;92:160-163

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collins, L. J.
Right arrow Articles by Manning, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collins, L. J.
Right arrow Articles by Manning, W. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Thinners
*Heart Disease in Women
*Heart Diseases
Hazardous Substances DB
*WARFARIN

(Circulation. 1995;92:160-163.)
© 1995 American Heart Association, Inc.


Articles

Cardioversion of Nonrheumatic Atrial Fibrillation

Reduced Thromboembolic Complications With 4 Weeks of Precardioversion Anticoagulation Are Related to Atrial Thrombus Resolution

Presented in part at the 67th Scientific Sessions of the American Heart Association, Dallas, Tex, November 14-17, 1994.

Laura J. Collins, MD; David I. Silverman, MD; Pamela S. Douglas, MD; Warren J. Manning, MD

From the Charles A. Dana Research Institute and the Harvard-Thorndike Laboratory of the Department of Medicine, Cardiovascular Division (L.J.C., P.S.D., W.J.M.), Beth Israel Hospital and Harvard Medical School, Boston, Mass, and the Cardiology Division of the John Dempsey Hospital and University of Connecticut Health Center, Farmington, Conn (D.I.S.).

Background The use of warfarin anticoagulation for several weeks before cardioversion results in a 90% reduction in the incidence of cardioversion-related thromboembolism. The mechanism of this benefit, however, is unknown; it has been widely attributed to organization and adherence of atrial thrombi, a finding observed among pathological studies of patients with rheumatic valvular disease.

Methods and Results Serial transesophageal echocardiography was performed in 14 patients with nonrheumatic atrial fibrillation after identification of atrial thrombi on initial transesophageal study. All patients received warfarin anticoagulation and were followed clinically for signs of thromboembolism. Eighteen atrial thrombi were identified on initial transesophageal study, including 14 thrombi confined to the left atrial appendage, 2 in the body of the left atrium, 1 in the right atrial appendage, and 1 in the body of the right atrium. Thrombus size varied from 5 to 20 mm, and 6 were considered mobile. After a median of 4 weeks of warfarin, 16 of 18 atrial thrombi (89%; 95% CI, 73% to 100%) had completely resolved on transesophageal echocardiographic study. In addition, no new thrombi were identified on follow-up study, and no patient had a clinical thromboembolic event between studies.

Conclusions These data strongly support the hypothesis that among patients with nonrheumatic atrial fibrillation, the mechanism of clinical benefit with 3 to 4 weeks of warfarin before cardioversion is related to thrombus resolution and prevention of new thrombus formation rather than thrombus organization.


Key Words: echocardiography • fibrillation • electric stimulation • arrhythmia




This article has been cited by other articles:


Home page
ChestHome page
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 546S - 592S.
[Abstract] [Full Text] [PDF]


Home page
Emerg. Med. J.Home page
R. Body and B. Allie
Negative D-dimer may allow safe early cardioversion of atrial fibrillation
Emerg. Med. J., June 1, 2007; 24(6): 432 - 435.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
O. M. Wazni, H.-M. Tsao, S.-A. Chen, H.-H. Chuang, W. Saliba, A. Natale, and A. L. Klein
Cardiovascular Imaging in the Management of Atrial Fibrillation
J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2077 - 2084.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): 700 - 752.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030.
[Full Text] [PDF]


Home page
ChestHome page
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 429S - 456S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Seidl, M. Rameken, A. Drogemuller, M. Vater, A. Brandt, H. Schwacke, C. Bergmeier, R. Zahn, and J. Senges
Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion: Final results of the Ludwigshafen Observational Cardioversion Study
J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1436 - 1442.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Circulation, October 23, 2001; 104(17): 2118 - 2150.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923.
[PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. L. Klein, R. D. Murray, and R. A. Grimm
Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation
J. Am. Coll. Cardiol., March 1, 2001; 37(3): 691 - 704.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Bollmann, K.-H. Binias, F. Grothues, K. Sonne, H.-D. Esperer, P. Nikutta, and H. U. Klein
Left Atrial Appendage Flow in Nonrheumatic Atrial Fibrillation : Relationship With Pulmonary Venous Flow and ECG Fibrillatory Wave Amplitude
Chest, February 1, 2001; 119(2): 485 - 492.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, J. E. Dalen, A. Laupacis, W. J. Manning, P. Petersen, and D. E. Singer
Antithrombotic Therapy in Atrial Fibrillation
Chest, January 1, 2001; 119(1_suppl): 194S - 206S.
[Full Text] [PDF]


Home page
EuropaceHome page
G. Corrado, M. Santarone, S. Beretta, G. Tadeo, L.M. Tagliagambe, G. Foglia-Manzillo, M. Spata, E. Miglierina, F. Acquati, and M. Santarone
Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: A single centre 8{middle dot}5-year experience
Europace, January 1, 2000; 2(2): 119 - 126.
[Abstract] [PDF]


Home page
StrokeHome page
J. L. Blackshear, L. A. Pearce, R. G. Hart, M. Zabalgoitia, A. Labovitz, R. W. Asinger, and J. L. Halperin
Aortic Plaque in Atrial Fibrillation : Prevalence, Predictors, and Thromboembolic Implications
Stroke, April 1, 1999; 30(4): 834 - 840.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. I. Silverman and W. J. Manning
Role of Echocardiography in Patients Undergoing Elective Cardioversion of Atrial Fibrillation
Circulation, August 4, 1998; 98(5): 479 - 486.
[Abstract] [Full Text] [PDF]


Home page
JWatch GeneralHome page
HOW ANTICOAGULATION MAY PREVENT EMBOLISM AFTER CARDIOVERSION
Journal Watch (General), July 25, 1995; 1995(725): 8 - 8.
[Full Text]